Kiniksa Pharmaceuticals International KNSA · USD
Health Care · US listing · 🇺🇸 United States
93.90
+0.38%
Close of 20 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
Price performance
Chart by TradingView, with its own licensed prices
- Market value
- $7.42bn
- Last close × shares
- Volume
- 545.2k
- Shares, 20 Nov 2026
- Price to earnings
- 128.7
About Kiniksa Pharmaceuticals International
From its filings with the US Securities and Exchange Commission
Kiniksa Pharmaceuticals International is based in London. Its shares trade on Nasdaq under the ticker KNSA. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $677.6m and net income of $59.0m. At that date it held total assets of $763.6m and shareholders' equity of $567.6m.
We are a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Our portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation.
ARCALYST is an interleukin-1α (“IL-1α”) and interleukin-1β (“IL-1β”) cytokine trap. In 2017, we licensed ARCALYST from Regeneron, which discovered and initially developed the drug. Our exclusive license to ARCALYST from Regeneron includes worldwide rights, excluding the Middle East and North Africa, for all applications other than those in oncology and local administration to the eye or ear.
We received FDA approval of ARCALYST for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children 12 years and older in March 2021. Recurrent pericarditis is a painful inflammatory cardiovascular disease with an estimated United States prevalent population of approximately 40,000 patients seeking and receiving medical treatment. ARCALYST is also approved in the United States for the treatment of Cryopyrin-Associated Periodic Syndromes (“CAPS”), including Familial Cold Autoinflammatory Syndrome (“FCAS”) and Muckle-Wells Syndrome in adults and children 12 years and older, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist (“DIRA”) in adults and children weighing 10 kg or more.
Quoted from its 10-K, filed 24 Feb 2026. Read the filing on SEC.gov ↗
Latest on Kiniksa Pharmaceuticals International
Our reporting
- Kiniksa Pharmaceuticals International down 2.18% on Monday
- Kiniksa Pharmaceuticals International down 3.79% on Tuesday
- Kiniksa Pharmaceuticals International up 5.22% on Monday
- Kiniksa Pharmaceuticals International up 6.25% on Friday
- Kiniksa Pharmaceuticals International up 3.03% on Wednesday
- Kiniksa Pharmaceuticals International up 2.74% on Tuesday
Next results
Due on 23 Feb 2027. Analysts expect earnings of 0.29 a share.
Other Health Care listings
Scenario calculator
Try your own numbers. This is arithmetic, not a forecast.
Gain or loss
Return
Leaves out fees, taxes and financing.
Frequently asked questions
What is Kiniksa Pharmaceuticals International's ticker?
Kiniksa Pharmaceuticals International trades as KNSA on its US listing, under ISIN GB00BRXB0C07.
What was Kiniksa Pharmaceuticals International's last closing price?
93.90 on 20 Nov 2026. The figure is in USD and is never converted.
When does Kiniksa Pharmaceuticals International next report results?
Results are expected on 23 Feb 2027, according to our data supplier.
Sources and methodology
- Chart
- TradingView
- Close and company data
- SEC filings and our data supplier
- News
- Our reporting
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.